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episode initiation. The date of ﬁrst mania-related visit after
depression was the index date of manic-switching for cases and
a random date was assigned for controls. Based on the pharmacy
records, 2050 patients were established having treatment of anti-
depressant monotherapy, mood stabilizer monotherapy, or anti-
depressant-mood stabilizer combination therapy within 30 days
prior to the index date. A logistic regression with difference-
in-difference approach was employed to predict the probabilities
of having manic-switching by different types of treatment.
RESULTS: Patients with antidepressant monotherapy and anti-
depressant-mood stabilizer combination therapy were 31% (n =
87) and 29% (n = 82) in the case group and 43% (n = 768) and
27% (n = 481) in the control group. Using logistic regression to
adjust for patient demographics, clinical-related and health-
related variables, the odds ratios for having manic-switching 
in relation to antidepressant monotherapy and antidepressant-
mood stabilizer combination therapy were 2.71 (95% CI:
1.32–5.56; p < 0.01) and 1.51 (95% CI: 0.81–2.81; p = 0.20)
respectively, compared to mood stabilizer monotherapy. CON-
CLUSIONS: This study further validates the national practice
guidelines for bipolar disorder with a case-control study design,
which does not have the study limitations of typical intent-to-
treat approach. Similar results were identiﬁed, indicating a risk
of induced manic-switching by antidepressant monotherapy yet
not by antidepressant-mood stabilizer combination therapy with
second-generation antidepressants.
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OBJECTIVES: Newer atypical antipsychotic medications were
recently approved by the FDA for treatment of bipolar disorder.
Although cost-effective pharmacotherapy can signiﬁcantly lower
total medical utilization and costs, economic evaluation studies
of pharmacotherapy in bipolar disorder are limited, particularly
for aytypical antipsychotics. This report reviews and identiﬁes
gaps in the current literature regarding impact of pharma-
cotherapy on health care utilization and costs among bipolar
patients. METHODS: A literature search was conducted using
Medline, CINHAL, International Pharmaceutical Abstracts and
Cochrane Collaborative databases for studies published between
January, 1990 and November, 2004. Abstracts presented at
American Psychiatric Association, National Institute of Mental
Health, and International Society of Pharmacoeconomics and
Outcomes Research were also examined. Articles were reviewed
to determine relevance to health care cost and utilization out-
comes associated with bipolar disorder pharmacotherapy.
RESULTS: The systematic search identiﬁed two randomized con-
trolled trials, two studies using administrative claims databases,
two studies using retrospective chart reviews and one study using
decision-modeling. Two studies reported that atypical antipsy-
chotic olanzapine reduced hospitalizations as compared to
placebo and typical antipsychotics. There were no studies com-
paring outcomes between different atypical antipyschotics for
bipolar disorder. Studies evaluating multiple endpoints between
ﬁrst-line pharmacotherapy and combinations of adjunct phar-
macotherapy were also lacking. Divalproex exhibited better cost
and utilization outcomes as compared to other pharmacothera-
pies (olanzapine, lithium and carbamazepine). Reduction in total
direct costs of bipolar disorder with use of any pharmacother-
apy was mostly attributable to reduced hospital stay. CON-
CLUSIONS: It is difﬁcult to compare utilization and cost
outcomes between pharmacotherapies due to the lack of head-
to-head studies, differences in research design and population
characteristics, and lack of cost-effectiveness studies determining
relative value of each pharmacotherapy for bipolar disorder.
Comprehensive evaluations of the impact of therapy on differ-
entiated economic endpoints relevant to practice policies (drug
costs, outpatient costs, hospitalizations, emergency room visits)
are needed.
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OBJECTIVES: To evaluate the effect of the July, 2001 prescrip-
tion limit policy change in the South Carolina Medicaid program
on the utilization of health care services and their related costs
for adult Medicaid recipients diagnosed with schizophrenia 
or bipolar disorder. METHODS: A retrospective cohort study
design, identifying subjects with schizophrenia and bipolar dis-
order compared their utilization of health care services and asso-
ciated costs 18-months before and after the policy change (July,
2001). Eligible patients were age 21 or older, had a qualifying
diagnosis on a hospital or ambulatory claim, and a prescription
medication for their diagnosis within 90 days (+/-) of their 1998
or 1999 enrollment date. Total health care cost and service uti-
lization were estimated by ordinary least squares regres-
sion models and the results contrasted with panel regression
methods due to the short time series. Predictor variables were
demographics, inpatient hospitalization, and comorbidities.
RESULTS: OLS and panel estimation show an increase in total
cost and the number of ambulatory, hospital, prescription, and
nursing home claims after the policy change. Panel estimation
shows a positive monthly trend in the post period for all claims.
CONCLUSIONS: The policy change resulting in an increase in
average monthly patient prescription cost is associated with
increases in total cost of care and overall health care utilizations.
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OBJECTIVES: When conducting analysis using observational
data, there is often selection bias for which we must account for
in order to adjust for pre-treatment differences between groups
in baseline characteristics. This study compared the ordinary
regression, propensity score weighting, propensity score match-
ing, and difference-in-difference (DD) methods while addressing
the impact of second-generation antidepressant use in adult
patients with bipolar disorder. METHODS: A logit model was
developed, as an ordinary approach, to predict the probability
of having post-index mania-related visits from treatment types,
controlling for individual demographics, clinical-related vari-
ables, health-related variables, and pre-index mania-related
visits, serving as the baseline disease severity of bipolar disorder.
The propensity score method added more bipolar severity vari-
ables to predict the propensity to be with one treatment type,
without the problem of over-parameterization in the outcome
model. Both weighting and greedy matching approaches were
applied after the ﬁrst-stage propensity score model achieved the
covariates balancing. For DD model, a logistic regression was
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employed to predict the probability of having mania-related
visits in pre-index or post-index period from treatments and 
time ﬁxed-effect, controlling for other covariates. RESULTS: The
ordinary regression indicated a protective effect on mania-related
visits from antidepressant monotherapy compared to mood sta-
bilizer monotherapy (OR = 0.66, 95% CI: 0.49–0.90), without
good control of baseline disease severity. Both propensity score
weighting and matching generated statistically indifferent out-
comes between treatment types. The results of the DD model
identiﬁed a signiﬁcant odds-ratio of 2.40 (95% CI: 1.52–3.79),
suggesting an adverse outcome of increased mania-related visits
with antidepressant monotherapy compared to mood stabilizer
monotherapy. CONCLUSIONS: Ordinary regression, propen-
sity score, and DD methods can produce inconsistent outcomes
when background characteristics are quite different and/or not
all potential confounders can be correctly measured and fully
controlled in the model. DD model may be considered in
outcome studies when pre-and-post data structure is available.
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OBJECTIVES: To derive a patient-based model of quality of 
life (QoL) for bipolar disorder (BPD). METHODS: Qualitative
research methods were employed to investigate the impact of
BPD on QoL. Speciﬁcally, to identify how patients perceive their
condition to affect their life quality and how they deﬁne “QoL”.
Semi-structured interviews were conducted with women with a
clinical diagnosis of BPD. Interpretive phenomenological analy-
sis (IPA) was used to explore and interpret participants’ percep-
tions of QoL impact. IPA involves two stages: a case-by-case
thematic analysis, and an interpretive analysis to connect and
cluster themes. For the latter, emphasis was placed on interpret-
ing the meaning and importance ascribed by patients to the
impact of BPD. The data were then compared to existing models
of QoL to derive a QoL model for BPD. RESULTS: As IPA
requires small sample sizes, interviews were conducted with four
women (26–92 (mean 49.5) years). Psychometric tests were
employed to ensure that the women were not currently depressed
(BDI) or manic (SCAN, MRS). Analysis revealed that BPD has
a profound impact on affected individuals. Thematic analysis
identiﬁed key areas of impact including; social life, personal rela-
tionships, self-esteem, work life, fear of rejection and impact on
day-to-day activities. Interpretive analysis revealed eight key the-
matic clusters including; intimate personal relationships, social
impact and personal development/fulﬁllment. Relating these to
existing models of QoL suggested that a needs-based model of
QoL impact was the most appropriate for BPD. The model sug-
gested that areas of need adversely affected by BPD related to;
safety and security, belongingness and love needs; esteem; cog-
nitive needs and self-fulﬁllment. CONCLUSION: BPD impacts
many life areas. Application of IPA revealed that the needs-based
model of QoL can successfully be used to explain the patient’s
perception of, and response to, the symptomatic and functional
impact of the condition.
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OBJECTIVE: To assess treatment adherence to antipsychotic
monotherapy in bipolar/manic disorder. METHODS: A total of
18,158 antipsychotic monotherapy treatment episodes for
bipolar and manic disorders were identiﬁed from a claims data-
base (1999–2003) representing 50 million US insured. Adherence
measures included treatment compliance, captured by regularity
of prescription reﬁlls, and treatment duration. Atypicals included
risperidone, olanzapine, quetiapine, and ziprasidone; conven-
tional agents included haloperidol, perphenazine, thioridazine,
and thiothixene. Multiple regression adjusted for patient char-
acteristics. RESULTS: Quetiapine alone had signiﬁcantly (P <
0.05) greater compliance than the conventional agents and had
the highest compliance among the atypicals, which was signiﬁ-
cantly greater than for risperidone or olanzapine. Olanzapine
and ziprasidone demonstrated signiﬁcantly greater compliance
than risperidone. Daily dose was negatively associated with com-
pliance for all agents except quetiapine (P < 0.05 for risperidone
and the conventional agents), which had a positive, but non-
signiﬁcant association (P = 0.074). Quetiapine and risperidone
had signiﬁcantly longer treatment duration than olanzapine,
ziprasidone, and the conventional agents. All atypicals, except
ziprasidone, had signiﬁcantly lower odds of switching to another
psychotropic compared with conventional agents; quetiapine
had the lowest estimated odds ratio. CONCLUSION: Accord-
ing to claims data, treatment adherence for quetiapine ap-
pears higher than for other agents commonly prescribed 
for bipolar/manic disorder, possibly due to more favorable 
tolerability.
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OBJECTIVE: To assess patterns of dementia/Alzheimer disease
(AD) management and to investigate predictive factors of 
cognitive-enhancing agents (CEA) use. METHODS: A cross-
sectional study was conducted using 2000–2002 National
Medical Care Survey among elderly patients over the age of 60.
Dementia/AD status was deﬁned according to dementia-related
ICD-9 codes; additionally, patient visit characteristics and CEA
prescriptions associated with dementia/AD status were evaluated
using a logistic regression model. RESULTS: A total of 25,561
patient visit records were identiﬁed. Majority of the visits were
from white patients (90.2%) and approximately half of them
were made by male individuals (45.9%). Of the total visits, only
0.6% (155) had dementia/AD status. Most of the dementia/AD
visits were made by women (60.0%) and persons over the age
of 75 (67.7%). Dementia/AD visit records were predominantly
from white patients (93.5%) and were associated with public
insurance (74.8%; Medicare/Medicaid). Of the dementia/AD
visits, about half (46.5%) were prescribed with one or more CEA
and donepezil HCl was the most prevalent agent that was pre-
scribed (31.6%). Our logistic regression model evaluating pre-
dictive factors of CEA prescription revealed that physician’s
specialty was a strong predictor in the model; as psychiatrists
(OR = 5.5; p < 0.01) and neurologists (OR = 2.6; p < 0.03) were
more likely to prescribe CEA as compared to other physicians.
No other visit characteristics showed signiﬁcant association with
CEA use. CONCLUSION: Early detection and treatment of
dementia delays the progression of cognitive impairment. Con-
sidering the high prevalence of dementia/AD among the elderly
(8–10%) in the US, the study’s results show that dementia man-
